Actively Recruiting
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
Led by Fudan University · Updated on 2026-01-05
160
Participants Needed
1
Research Sites
137 weeks
Total Duration
On this page
Sponsors
F
Fudan University
Lead Sponsor
J
Jiangsu HengRui Medicine Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study is being conducted to evaluate the safety, tolerability and efficacy of ADC drugs monotherapy or combination therapy with HRS-4642 or immunotherapy in subjects with locally advanced or metastatic pancreatic cancer.
CONDITIONS
Official Title
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who volunteer and sign informed consent
- Age between 18 and 75 years, any gender
- Diagnosed with advanced (metastatic or unresectable) pancreatic cancer with at least one measurable tumor
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Life expectancy of at least 12 weeks
- Adequate bone marrow and organ function
- Female participants of childbearing age must have a negative pregnancy test within one week before treatment and agree to use effective contraception during the study and for three months after
- Male participants with partners of childbearing age must agree to use effective contraception during the study and for six months after
You will not qualify if you...
- Known allergy to the study drugs or their components
- Received systemic anti-cancer therapy within 4 weeks or palliative radiotherapy within 14 days before starting the study
- Presence of other active cancers within the last 5 years
- Untreated or active central nervous system metastases
- Not recovered from previous treatment side effects to acceptable levels
- Having interstitial lung disease, non-infectious pneumonia, severe uncontrolled diseases, acute infections, or recent major surgery within 28 days
- Gastrointestinal obstruction or related symptoms within 6 months unless fully relieved by surgery
- Severe cardiovascular or cerebrovascular events within 6 months prior to study entry
- Immune deficiencies such as HIV infection or active hepatitis B or C
- Active pulmonary tuberculosis within the past year or untreated history of tuberculosis
- Participation in other clinical studies with recent medication use
- High risk of pancreatitis with elevated enzyme levels
- Uncontrollable mental illness or substance abuse affecting study participation
- Major surgery other than diagnosis or biopsy within 28 days, or minor surgery within 7 days prior to treatment
- Other conditions deemed unsuitable by the researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
S
Si Shi, PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here